BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24714973)

  • 1. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
    Saloura V; Cohen EE; Licitra L; Billan S; Dinis J; Lisby S; Gauler TC
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1227-39. PubMed ID: 24714973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.
    Machiels JP; Subramanian S; Ruzsa A; Repassy G; Lifirenko I; Flygare A; Sørensen P; Nielsen T; Lisby S; Clement PM
    Lancet Oncol; 2011 Apr; 12(4):333-43. PubMed ID: 21377930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.
    Brøndum L; Alsner J; Sørensen BS; Maare C; Johansen J; Primdahl H; Evensen JF; Kristensen CA; Andersen LJ; Overgaard J; Eriksen JG
    Acta Oncol; 2018 Sep; 57(9):1159-1164. PubMed ID: 29771169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
    Vermorken JB; Peyrade F; Krauss J; Mesía R; Remenar E; Gauler TC; Keilholz U; Delord JP; Schafhausen P; Erfán J; Brümmendorf TH; Iglesias L; Bethe U; Hicking C; Clement PM
    Ann Oncol; 2014 Mar; 25(3):682-688. PubMed ID: 24567516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.
    Machiels JP; Specenier P; Krauß J; Dietz A; Kaminsky MC; Lalami Y; Henke M; Keilholz U; Knecht R; Skartved NJ; Horak ID; Pamperin P; Braun S; Gauler TC
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):13-20. PubMed ID: 25952795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
    Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Rischin D; Spigel DR; Adkins D; Wein R; Arnold S; Singhal N; Lee O; Murugappan S
    Head Neck; 2016 Apr; 38 Suppl 1():E1756-61. PubMed ID: 26681429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
    Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
    Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
    Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
    Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
    Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
    J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.
    Zhang S; Chen J; Jiang H; Ma H; Yang B
    Eur J Clin Pharmacol; 2012 May; 68(5):561-9. PubMed ID: 22231637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
    N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
    Guigay J; Lee KW; Patel MR; Daste A; Wong DJ; Goel S; Gordon MS; Gutierrez M; Balmanoukian A; Le Tourneau C; Mita A; Vansteene D; Keilholz U; Schöffski P; Grote HJ; Zhou D; Bajars M; Penel N
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Agulnik M
    Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Seiwert TY; Fayette J; Cupissol D; Del Campo JM; Clement PM; Hitt R; Degardin M; Zhang W; Blackman A; Ehrnrooth E; Cohen EEW
    Ann Oncol; 2014 Sep; 25(9):1813-1820. PubMed ID: 24928832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
    Machiels JP; Van Maanen A; Vandenbulcke JM; Filleul B; Seront E; Henry S; D'Hondt L; Lonchay C; Holbrechts S; Boegner P; Brohee D; Dequanter D; Louviaux I; Sautois B; Whenham N; Berchem G; Vanderschueren B; Fontaine C; Schmitz S; Gillain A; Schoonjans J; Rottey S
    Oncologist; 2016 Dec; 21(12):1416-e17. PubMed ID: 27903924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.